Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer. Issue 5 (10th February 2022)

Record Type:
Journal Article
Title:
Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer. Issue 5 (10th February 2022)
Main Title:
Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer
Authors:
Mo, Dun-Chang
Ren, Tao
Abstract:
Is Part Of:
Journal of clinical oncology. Volume 40:Issue 5(2022)
Journal:
Journal of clinical oncology
Issue:
Volume 40:Issue 5(2022)
Issue Display:
Volume 40, Issue 5 (2022)
Year:
2022
Volume:
40
Issue:
5
Issue Sort Value:
2022-0040-0005-0000
Page Start:
522
Page End:
523
Publication Date:
2022-02-10
Subjects:
Oncology -- Periodicals
Cancer -- Periodicals
Oncology
Medical Oncology
Cancérologie -- Périodiques
Cancer -- Périodiques
Cancérologie
Cancer
Oncology
Oncologia
Càncer
Periodicals
616.994
Journal URLs:
http://www.jco.org/ ↗
http://jco.ascopubs.org/ ↗
http://journals.lww.com/pages/default.aspx ↗
DOI:
10.1200/JCO.21.02208 ↗
Languages:
English
ISSNs:
0732-183X
Deposit Type:
Legaldeposit
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:
24780.xml